A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PP / primary progressive

[Related PubMed/MEDLINE]
Total Number of Papers: 195
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PP  (>> Co-occurring Abbreviation)
Long Form:   primary progressive
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis. MS, MTR, pu, SP
2019 Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients. MS, SP
2019 Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. EDSS, MS, RR, SP
2018 Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. EDSS, MS, RR
2018 Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients. CNS, HC, MS, PBMC
2018 Mid-term sustained relief from headaches after balloon angioplasty of the internal jugular veins in patients with multiple sclerosis. FSS, IJVs, MIDAS, MS, PTA, RR, SP
2018 New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. FDA, MS, OCR, RR
2018 Progress in understanding the pathophysiology of multiple sclerosis. MS, RR
2018 Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis. CNS, MS, RRMS
10  2017 Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. CI, CIS, EDSS, MS, PPMS, RR, SP
11  2017 Demographic and clinical profile of Multiple Sclerosis in Kashmir: A short report. CNS, CSF, INO, MS, OCB, RR, SP
12  2017 Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. APCs, EBV, HLA-DR, MS, TLRs
13  2017 Machine Learning Approach for Classifying Multiple Sclerosis Courses by Combining Clinical Data with Lesion Loads and Magnetic Resonance Metabolic Features. Cho, CIS, Cre, LDA, MS, NAA, RR, SP
14  2017 Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study. EDSS, LOMS, MS, RR
15  2017 Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. MS
16  2017 Progressive iron accumulation across multiple sclerosis phenotypes revealed by sparse classification of deep gray matter. CIS, CN, DGM, GP, MS, PU, QS, RR, SP, TH
17  2017 The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis. CSF, GA, MS, RGC, RRMS, SP
18  2016 B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity. BE, HC, MOG, MS, RR, SP
19  2016 Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings. CC/MISS, ERPs, MS, PCA, RR, SP, THIRDVW
20  2016 Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. MS, SP
21  2016 Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. BDI II, RR, SP
22  2016 Graph Theory-Based Brain Connectivity for Automatic Classification of Multiple Sclerosis Clinical Courses. CIS, DTI, HC, MS, RBF, RR, SP, SVM
23  2016 Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis. GM, MS, RR, SP, WM
24  2016 iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. CTR, IFN, MS, NAT, RR, SP, TNF
25  2016 Prevalence of Walking-Related Motor Fatigue in Persons With Multiple Sclerosis: Decline in Walking Distance Induced by the 6-Minute Walk Test. 6MWT, EDSS, PwMS, RR, SP
26  2016 Therapeutic strategies targeting B-cells in multiple sclerosis. CNS, MS, RR
27  2015 Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker. MRI, MS, RR
28  2015 Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis. CNS, MS, NP, RR
29  2015 MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. miR-572, MS, NCAM, RR, SP
30  2015 Mitochondrial DNA sequence variation in multiple sclerosis. CI, MS, mtDNA, OR
31  2015 Serum NSE level and disability progression in multiple sclerosis. EDSS, MS, MSSS, NSE, RR, SP
32  2015 Subclinical central inflammation is risk for RIS and CIS conversion to MS. CIS, CSF, IL-8, MS, RIS, RR
33  2015 Unmet needs of multiple sclerosis patients in the community. DMTs, NAQ, RR, SP
34  2014 A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility. CCR5-Delta32, MS, RR, SP
35  2014 Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course? MS, NA, RR, SP
36  2014 Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. DMDs, EDSS, esRAGE, HCs, MS, MSSS, RR, SP
37  2014 FADD is upregulated in relapsing remitting multiple sclerosis. FADD, MS, RR, SP, TNF, TRADD
38  2014 Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from individuals with clinically-isolated syndrome and different stages of multiple sclerosis. CIS, HC, MS, RR, SP
39  2014 Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study. MS, RR
40  2014 Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups. EDSS, MS, MTR, RR, SP
41  2014 Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. CNS, CSF, MRI, MS, RR, SP
42  2014 Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. FDE, MS, MSSS, pNF-H, RR, SP
43  2014 Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI. Cho, Cr, CSI, CST, Ins, MS, RR
44  2014 Ultrasonographic evaluation of cerebral arterial and venous haemodynamics in multiple sclerosis: a case-control study. CBF, CPP, CVF, MCA, MFV, MS, RR
45  2013 Alteration of prolyl oligopeptidase and activated alpha-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. CIS, MS, PREP, RR, SP
46  2013 Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. MS, NK, SP
47  2013 Cognitive impairment among different clinical courses of multiple sclerosis. ERR, HC, IPS, LRR, MS, RRMS, SP
48  2013 Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS. BRB, CCSVI, CI, CIS, FSS, GNDS, HDRS, MS, MSQoL54, RR, SP, ST
49  2013 Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability. CIS, EDSS, MS, RR, SP, TFIM
50  2013 Language abilities of patients with primary progressive multiple sclerosis: A preliminary group and case investigation. BNT, CP, MS, NCCEA, RR, SP, TLC-E
51  2013 MS cortical lesions on DIR: not quite what they seem? CGM, DIR, IC, LC, PSIR, RR, SP
52  2013 Pediatric multiple sclerosis with primary progressive course--report of a retrospective cohort study in Iran. IMSS, MRI, MS, PPMS
53  2013 Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease. MS, PD
54  2013 Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. EDSS, MR, MS, RR, SP, UCCA
55  2013 Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. CDP, RR
56  2013 Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case-control ultrasound study. CCSVI, CIS, EDSS, IJVs, MSSS, RR, SP
57  2013 Sulcal and gyral crown cortical grey matter involvement in multiple sclerosis: A magnetisation transfer ratio study. GM, MS, MTR, RR, SP
58  2013 T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. ALS, HC, MS
59  2013 The effects of identification with a support group on the mental health of people with multiple sclerosis. MS, RR, SP
60  2013 TRAF2 is upregulated in relapsing-remitting multiple sclerosis. MS, RIP, RR, SP, TNF, TRAF2
61  2013 Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. CIS, HC, MS, RR, SP
62  2012 Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis. GM, SP
63  2012 Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis. Cho, CSO, DTI, MRSI, MS, NAA, NAWM, RR, SP, T2-LL
64  2012 Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. CIS, Hcy, MS, NDC, RR, SP
65  2012 Implementation of an absolute brain 1H-MRS quantification method to assess different tissue alterations in multiple sclerosis. SP
66  2012 Late-onset multiple sclerosis in Isfahan, Iran. IMSS, LOMS, MS, PI, RR, SP
67  2012 Multigate quality Doppler profiles and morphological/hemodynamic alterations in multiple sclerosis patients. CCSVI, ECD, EDSS, IJVs, MS, RR
68  2012 Multiple sclerosis and CCSVI: a population-based case control study. CCSVI, CIS, ECD, MS, OND, RR, SP
69  2012 Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. CIS, MS, RNFL, RR, SP
70  2012 Type 1 immune response in progressive multiple sclerosis. MS, SP
71  2011 Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients. RRMS, SP
72  2011 Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. CI, CP, GM, MS, RR, SP
73  2011 Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. CSF, MS, OND, RR, SP
74  2011 Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. EDSS, IGF, IGFBP-3, MS, MSSS, RR, SP
75  2011 Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency. CCSVI, EDSS, MS, NC, SP
76  2011 Retinal periphlebitis in patients with multiple sclerosis. CNS, MS, RP, RR, SP, VEP's
77  2011 [Vitamin D and multiple sclerosis. A prospective survey of patients of Poitou-Charentes area]. MS
78  2010 Are somatosensory evoked potentials of the tibial nerve the most sensitive test in diagnosing multiple sclerosis? AEPs, CNS, MEPs, MRI, MS, RR, SEPs, VEPs
79  2010 Default-mode network dysfunction and cognitive impairment in progressive MS. ACC, DMN, DT, ICA, mPFC, MS, PCG, RS, SP, WM
80  2010 Disease onset in familial and sporadic primary progressive multiple sclerosis. MS
81  2010 Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. CNS, CSF, hK6, MS, RR, SP
82  2010 Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. cLPM, CLs, DIR, LPMs, MS, RR
83  2010 Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Cbl, CNS, CSF, EGF, MS, NGF, RR, SP, TNF
84  2010 Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? 9HPT, MS, MSFC, PASAT, T25FW
85  2010 Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. CSF, MScl, RR
86  2010 Sex ratio of multiple sclerosis and clinical phenotype. MS, RR
87  2009 A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. AZY, CCSVI, IJVs, MR, MS, PTA, QOL, RR, SP
88  2009 Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. ASI, CSF, ELISA, IgG, MRI, MS, NIND, OIND, RR, SP
89  2009 Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. CIS, EBNA1, EBV, Gd, IgG, MS, RR, VCA
90  2009 Plasma endocannabinoid levels in multiple sclerosis. AEA, EC, FAAH, MS, PEA, RR, SP
91  2009 Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. CSF, DIS, MS, RR
92  2009 Primary progressive multiple sclerosis: tactile-associated functional MR activity in the cervical spinal cord. MR, MS
93  2009 The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? OPN, RR, SP
94  2009 Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. IL, MS, SNPs, SP
95  2008 A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. CIS, GM, LV, MS, RR, SP, VBM
96  2008 Cognitive impairment in different MS subtypes and clinically isolated syndromes. BRB-N, CIS, RR, SP
97  2008 Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. CSA, EDSS, MS, MT, MTR, NAGM, NBV
98  2008 Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. EDSS, LRs, MS, MSFC, RR
99  2008 The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study. MS, RR-A, SP, SP-A, SP-S, sTfR, TfR
100  2007 Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis. CHIP, FAB, HAM-A, MADRS, MINI, MS, QOL, RR, SP, WCC